NSE · VIVOBIOT
Vivo Bio Tech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹0 Cr — a 1.27% net margin, versus -39.51% the period before.
Shareholding
As of 2026-06-30
- Promoter30.62%
- Public69.38%
21,224 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.27× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 4.81 percentage points to 30.62% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #84 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,41,478 Cr | 34.94 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,631 Cr | 22.86 | 4.12 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,353 Cr | 30.84 | 3.2 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,06,387 Cr | 97.28 | 20.09 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹97,282 Cr | 30.19 | 2.55 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹96,652 Cr | 25.56 | 2.54 | 9.25% | 10.7% |
| Lupin Limited | ₹95,797 Cr | 16.08 | 4.27 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹94,174 Cr | 44.14 | 5.77 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,276 Cr | 21.88 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,713 Cr | 87.27 | 1.85 | 1.14% | 2.89% |
| Vivo Bio Tech Ltd.(this company) | ₹38 Cr | — | 0.41 | -1.83% | -5.17% |
AI analysis
AI-generated · google/gemini-2.5-flashVivo Bio Tech Ltd. is listed on the Indian markets with a market capitalization of Rs 51 Cr. The company reported a negative profit margin of -5.17% and an EPS of 0. Its return on equity (ROE) is -183.43%, while return on capital employed (ROCE) is 6.6394%. The debt-to-equity ratio stands at 0.96. The 52-week high for the share price was Rs 43.35 and the 52-week low was Rs 20.35. Promoter holding is 30.6188% as of June 30, 2026, with public holding at 69.3812%.
Positives
- +The return on capital employed (ROCE) is 6.6394%.
Negatives
- −The company reported a negative profit margin of -5.17%.
- −Return on equity (ROE) is negative at -183.43%.
- −The earnings per share (EPS) is 0.
- −The debt-to-equity ratio of 0.96 indicates a significant reliance on debt.
- −Promoter holding decreased from 30.6188% in Jun 2026 to no data available for subsequent periods, indicating a lack of recent disclosure.
- −No DII or FII shareholding was reported as of June 30, 2026.
- −Quarterly results have not been disclosed for periods after June 2026.
Financial performance
In the quarter ending March 2026, Vivo Bio Tech Ltd. reported revenue of Rs 14.2 Cr, decreasing slightly to Rs 14.28 Cr in June 2026. Net profit in March 2026 was -Rs 5.16 Cr, improving to Rs 0.19 Cr in June 2026. EBITDA for the quarter ending March 2026 was Rs 2.33 Cr, followed by Rs 1.58 Cr in June 2026.
Profitability & returns
The company's profit margin is -5.17%. Return on equity (ROE) is -183.43%, indicating that the company is not generating positive returns for its shareholders. The return on capital employed (ROCE) is 6.6394%. The earnings per share (EPS) is 0.
Balance sheet
The debt-to-equity ratio for Vivo Bio Tech Ltd. is 0.96. The book value per share is Rs 41.25. The company does not have a dividend yield, reported as 0.
Ownership & pledges
Public shareholding stands at 69.3812%. There is no promoter pledge reported (0%). The number of shareholders as of June 30, 2026, was 21224. There has been no DII or FII holding reported.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.